Zhejiang Provincial People's Hospital-Oncology (Site 0656)
Welcome,         Profile    Billing    Logout  
 2 Trials 
7 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mou, Yiping
KEYNOTE-585 China Extension study, NCT04882241: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension

Active, not recruiting
3
120
RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Placebo, Normal saline solution, Cisplatin, PLATINOL®, Capecitabine, XELODA®, 5-fluorouracil, ADRUCIL®, 5FU, Docetaxel, TAXOTERE®, Oxaliplatin, ELOXATIN®, Leucovorin, WELLCOVORIN®
Merck Sharp & Dohme LLC
Gastric Cancer, Gastroesophageal Junction Cancer
02/24
04/25
ENREACH-PDAC-01, NCT05149326: KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.

Active, not recruiting
3
408
RoW
KN046, placebo
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Pancreatic Ductal Adenocarcinoma
04/24
08/24
AK104-217, NCT05859750: A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer

Recruiting
2
78
RoW
AK104, Gemcitabine, Nab-Paclitaxel, Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate, Oxaliplatin + Irinotecan + 5-Fluorouracil/Leucovorin
Akeso
Pancreatic Cancer
06/25
12/25
NCT05934331: A LM-302 Combined With Toripalimab Phase II Study

Recruiting
2
276
RoW
LM302+Toripalimab, LM302+JS001
LaNova Medicines Zhejiang Co., Ltd.
Gastric Cancer, Pancreatic Cancer
07/25
01/26
NCT04228601: A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer

Completed
1/2
39
RoW
Fluzoparib, SHR3162, Fluzoparib placebo, mFOLFIRINOX
Jiangsu HengRui Medicine Co., Ltd.
Advanced Pancreatic Cancer
08/22
01/23
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors

Recruiting
1
470
US, RoW
IBI343
Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed
Locally Advanced Unresectable or Metastatic Solid Tumors
12/25
12/25
NCT05911217: A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer

Recruiting
1
20
RoW
CT041 autologous CAR T-cell injection, Single Group Assignment
CARsgen Therapeutics Co., Ltd., Fudan University
Pancreatic Cancer
12/26
12/26

Download Options